BioSpace News Archive

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its third quarter 2020 financial results and operational highlights in a conference call on November 5, 2020 at 8 a.m. ET. To join the call: U.S. callers should dial 1-877-317-6789 and international callers should dial 1-412-317-6789, approximately f

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 5, 2020. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will be available on the Co

vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will make an oral presentation at the 13 th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event on November 4, 2020. The presentation will provide a general study update and data on the baseline characteristics of patients enrolled in the ongoing phase 2 Elevage Study of azeliragon as a potential treatment for mild-probable Alzheimer’s disease (AD) in adult patients who a

Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced a key achievement in the verification of its preeclampsia rule-out test, a significant milestone demonstrating the robustness of the underlying assays

Initial information sharing agreement signed to further research into the anti-viral potential of WP1122

- HB-202/HB-201 alternating two-vector therapy is added as an additional arm that expands the ongoing HB-201 clinical trial - Pre-clinical data show that adding an additional arenaviral vector to achieve alternating two-vector therapy enhances immune response

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, issued the following letter to shareholders.

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020.

PellePharm, Inc., a BridgeBio Pharma, Inc. company, today announced the presentation of various data highlighting product candidate patidegib topical gel for adults with Gorlin syndrome and high-frequency basal cell carcinoma (HF-BCC). The presentations will be made during the 29th Congress of the European Academy of Dermatology and Venereology (EADV), to be held virtually October 29 – 31, 2020. Patidegib topical gel

Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it held an End-of-Review conference as a Type A meeting with the Division of Cardiology and Nephrolo